Actinium Pharmaceuticals, Inc.
(NYSE Amex Equities : ATNM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.64%301.291.4%$584.72m
AMGNAmgen, Inc.
0.17%233.801.3%$518.78m
GILDGilead Sciences, Inc.
1.87%67.161.0%$370.38m
REGNRegeneron Pharmaceuticals, Inc.
0.99%371.972.6%$303.45m
VRTXVertex Pharmaceuticals, Inc.
0.01%223.091.9%$268.14m
ILMNIllumina, Inc.
1.91%325.913.5%$237.53m
ARWRArrowhead Pharmaceuticals, Inc.
2.64%67.2612.0%$192.15m
EXASEXACT Sciences Corp.
2.89%86.0324.0%$183.60m
ALXNAlexion Pharmaceuticals, Inc.
5.95%113.812.0%$180.25m
CLVSClovis Oncology, Inc.
7.90%9.5614.7%$174.93m
SRPTSarepta Therapeutics, Inc.
-0.33%109.6014.6%$148.34m
AAgilent Technologies, Inc.
0.73%82.131.6%$141.52m
BMRNBioMarin Pharmaceutical, Inc.
0.19%80.234.3%$130.34m
SGENSeattle Genetics, Inc.
0.04%117.216.1%$127.94m
NBIXNeurocrine Biosciences, Inc.
0.24%116.765.0%$127.87m

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.